DownRightNowNews
Trending
Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drugENERGY WATCH: Boom and doomKering's Alexander McQueen creative director Sean McGirr to leaveSchool headscarf ban sparks rare protests in Azerbaijan and row with TurkeyDozens reportedly injured in police crackdown on Portugal housing protestRevolution Medicines' Europe efforts signal solo launch ambitions for cancer drugENERGY WATCH: Boom and doomKering's Alexander McQueen creative director Sean McGirr to leaveSchool headscarf ban sparks rare protests in Azerbaijan and row with TurkeyDozens reportedly injured in police crackdown on Portugal housing protest
Business

Duolingo Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Duolingo, Inc.

·2h ago
Share:PostShare

NEW ORLEANS, Oct. 15, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against Duolingo, Inc. (“Duolingo” or the “Company”) (NasdaqGS: DUOL), if they purchased Duolingo, Inc. Class A common stock between May 2, 2025 and February 26, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Pennsylvania.

G

Globenewswire_fr

Original source

Read full story
EducationTechnologyBanking & Finance

Related Stories

Business8h ago

Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis

VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”) has reached its enrollment target.

GGlobe Newswire
Business8h ago

Apterra Infrastructure Capital Names Josh Mintz Chief Financial Officer

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Apterra Infrastructure Capital (“Apterra” or the “Company”), a leading infrastructure finance platform and affiliate of Apollo (NYSE: APO), today announced that Josh Mintz has joined Apterra as Chief Financial Officer. Mintz brings more than 15 years of experience across private credit, alternative asset management and financial services, and will report to Co-CEOs Michael Pantelogianis and Ralph Cho.

GGlobe Newswire

Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.

Read Disclaimer